Novavax will supply its vaccine to the EU from the end of 2021

As reported, the American company may sign a contract with the European Union as early as this week.

Novavax said it plans to start shipping its vaccine to the European Union by the end of this year, with a formal contract expected to be signed as early as this week, an EU official told Reuters.

According to the source, under this contract, Novavax will supply up to 200 million doses of the vaccine, providing the EU with booster injections that will help contain the spread of the coronavirus and potentially protect the population from new strains.

The American company entered into a preliminary agreement with the EU in December, but the conclusion of a formal agreement was postponed because Novavax had difficulties with the supply of raw materials.

An EU source said Novavax still faces some production challenges, but that the company now has a delivery schedule.

In meetings with EU authorities over the past two weeks, the company said it plans to ship the first small shipments by the end of this year, with the bulk delivered in 2022.

A spokesman for the European Commission, which is negotiating with vaccine manufacturers along with the governments of the bloc’s 27 countries, declined to comment for privacy reasons.

According to Novavax, negotiations with the EU are continuing. The company declined to comment on delivery dates, production problems, or the planned conclusion of a formal agreement.

The supply of the Novavax vaccine to the EU requires regulatory approval. The European Medicines Agency has not yet set a date for a decision on the vaccine, which is not yet approved anywhere in the world.

The European Commission has repeatedly expressed confidence that it has contracted for enough doses to vaccinate at least 70 percent of the adult population by the end of July. The World Health Organization says about 70 percent of the population needs to be vaccinated to stop the spread of the virus.

According to the EU representative, the Novavax vaccine is an “alternative or supplement” to the matrix RNA vaccine produced by Pfizer.

Author: Steve Cowan
Graduated From Princeton University. He has been at the Free Press since October 2014. Previously worked as a regional entertainment editor.
Function: Chief-Editor